Transient myeloproliferative disorder associated with trisomy 21: Is a short course of chemotherapy indicated in patients with liver impairment and severe clinical problems?

Medical and Pediatric Oncology

Volumn 32, Issue 6, 1999, Pages 453-454

  Rizzari, Carmelo ^a   Malberti, R ^a   Dell'Orto, M ^a   Milani, M ^a   Jankovic, M ^a   Ferrari, E ^a   Conter, V ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cancer chemotherapy; Childhood cancer; Down syndrome; Megakaryocytes; Nonlymphocytic leukemia

Indexed keywords

ACUTE MEGAKARYOCYTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; CASE REPORT; DISEASE ASSOCIATION; HUMAN; INFANT; LIVER DISEASE; MALE; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; TREATMENT INDICATION; TRISOMY 21;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; DOWN SYNDROME; DRUG ADMINISTRATION SCHEDULE; DYSPNEA; FEVER; HEPATOMEGALY; HUMANS; INFANT, NEWBORN; MALE; MUSCLE WEAKNESS; MYELOPROLIFERATIVE DISORDERS; NUTRITION DISORDERS; SPLENOMEGALY;

EID: 0033011360     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199906)32:6<453::AID-MPO14>3.0.CO;2-X     Document Type: Article

References (12)

1. Zipursky A, Poon A. Ooyle J. Leukemia in Down syndrome: a review. Fed Hematol Oncol 1992;9:139-142.
2. Zerres K, Schwanitz G, Niesen M, et al. Prenatal diagnosis of acute nonlymphoblastic leukemia in Down syndrome. Lancet 1990;335:117-118.
3. Kalousek OK, Chan KW. Transient myeloproliferative disorder in chromosomally normal newborn infant. Med Pediatr Oncol 1987; 15:38-41.
4. Zubizarreta P, Sackmann Muriel F, Fernandez Barbieri MA. Transient myeloproliferative disorder associated with trisomy 21: report of two cases with trisomy 21 mosaicism. Med Pediatr Oncol 1995;25:60-64.
5. Schwab M, Niemeyer C, Schwarzer U. Down syndrome, transient myeloproliferative disorder, and infantile liver fibrosis. Med Pediatr Oncol 1998;31:159-165.
6. Litz CE, Davies S, Brunning RD, et al. Acute leukemia and the transient myeloproliferative disorder associated with Down syndrome: morphologic, immunophenoptypic and cytogenetic manifestations. Leukemia 1995;9:1432-1439.
7. Hayashi Y, Eguchi M, Sugita K, et al. Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down's syndrome. Blood 1988;72:15-23.
8. Brodeur GM, Dahk GV, Williams DL, et al. Transient leukemoid reaction and trisomy 21 mosaicism in a phenotipically normal newborn. Blood 1980;55:341-345.
9. Kurahashi H, Junichi H, Keiko Y, et al. Monoclonal nature of transient abnormal hematopoiesis in Down's syndrome. Blood 1991;77:1161.
10. Homans AC, Verissimo AM, Vlacha V. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol 1993;15:392-399.
11. Miyauchi J, Ito Y, Kawano T, et al. Unusual diffuse liver fibrosis accompanying transient myeloproliferative disorder in Down's syndrome: a report of four autopsy cases and proposal of a hypothesis. Blood 1992;80:1521-1527.
12. Taub JW, Stout ML, Buck SA, et al. Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin. Leukemia 1997;11:1594-1597.